Published in Br J Pharmacol on April 10, 2007
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med Chem (2009) 1.09
Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85
Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause (2017) 0.76
Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important? Clin Exp Metastasis (2011) 0.76
Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause (2015) 0.75
In Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract Osteoporosis. Evid Based Complement Alternat Med (2012) 0.75
Effects of CreERT2, 4-OH Tamoxifen, and Gender on CFU-F Assays. PLoS One (2016) 0.75
Incorporation of raloxifene-impregnated allograft around orthopedic titanium implants impairs early fixation but improves new bone formation. Acta Orthop (2014) 0.75
Tamoxifen stimulates calcitonin-producing thyroid C-cells and prevents trabecular bone loss in a rat model of androgen deficiency. J Anat (2015) 0.75
Measuring selective estrogen receptor modulator (SERM)-membrane interactions with second harmonic generation. J Am Chem Soc (2014) 0.75
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev (1998) 7.81
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Evidence of estrogen receptors in normal human osteoblast-like cells. Science (1988) 2.85
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun (1998) 2.66
Estrogen receptors alpha and beta are differentially expressed in developing human bone. J Clin Endocrinol Metab (2001) 2.23
Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A (2000) 2.20
Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science (1996) 1.95
Sex steroids and bone. Physiol Rev (2001) 1.88
Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci U S A (1991) 1.65
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest (1994) 1.55
Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun (1998) 1.33
Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol (2004) 1.28
Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. Calcif Tissue Int (2005) 1.23
Expression and localization of estrogen receptor-beta in murine and human bone. J Bone Miner Res (1999) 1.22
Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol (1995) 1.18
Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology (1988) 1.18
Localization of estrogen receptor beta protein expression in adult human bone. J Bone Miner Res (2001) 1.15
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J (1996) 1.14
The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone (2002) 1.14
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res (2005) 1.12
Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis (2005) 1.12
A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res (1996) 1.11
Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem (2000) 1.08
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci (1995) 1.07
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst (1992) 1.04
Tamoxifen ("Nolvadex"): a review. Cancer Treat Rev (2002) 1.04
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res (1991) 1.02
Age-related difference in tamoxifen disposition. Clin Pharmacol Ther (1996) 0.99
Overview of osteoporosis. West J Med (1991) 0.97
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology (2000) 0.96
Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med (1994) 0.96
Role of estrogen in postmenopausal depression. Neurology (1997) 0.95
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab (2006) 0.93
Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. J Clin Endocrinol Metab (2004) 0.93
Expression of estrogen receptor-alpha in cells of the osteoclastic lineage. Histochem Cell Biol (1999) 0.92
Selective toxic effects of tamoxifen on osteoclasts: comparison with the effects of oestrogen. J Endocrinol (1996) 0.92
The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int (1994) 0.92
Estrogen for women at varying risk of coronary disease. Maturitas (1998) 0.92
The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology (1994) 0.90
Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol (2003) 0.90
Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner (1993) 0.89
Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem (1999) 0.89
The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res (2003) 0.88
Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun (1998) 0.87
Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res (1987) 0.86
Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab (2003) 0.86
Mammalian mature osteoclasts as estrogen target cells. Biochem Biophys Res Commun (1996) 0.86
Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol (2004) 0.86
Gender- and age-related differences in osteoclast formation from circulating precursors. J Endocrinol (2002) 0.84
Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology (1996) 0.84
Estrogens, the menopause, and osteoporosis. Bone (1996) 0.83
Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol. J Natl Cancer Inst (1990) 0.83
Detection of estrogen receptor alpha, carbonic anhydrase II and tartrate-resistant acid phosphatase mRNAs in putative mononuclear osteoclast precursor cells of neonatal rats by fluorescence in situ hybridization. J Mol Endocrinol (1998) 0.82
Targeted anti-estrogens to treat and prevent diseases in women. Mol Med Today (1996) 0.81
Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression. J Steroid Biochem Mol Biol (2006) 0.80
Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. Eur Cytokine Netw (2002) 0.80
Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. J Endocrinol Invest (2002) 0.79
Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene. Maturitas (2004) 0.79
Preliminary in situ identification of estrogen target cells in bone. J Bone Miner Res (1995) 0.79
Steroid hormone modulation of vitamin D receptor levels in human MG-63 osteosarcoma cells. Biochem Biophys Res Commun (1994) 0.79
Hormone replacement therapy. Protection against the consequences of menopause. Postgrad Med (1992) 0.78
Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett (2002) 0.78
Sex steroid hormone receptors in normal and dysplastic bone disorders in children. J Bone Miner Res (1990) 0.77
Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. Endocrinology (1986) 0.77
[The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. Zhonghua Nei Ke Za Zhi (2003) 0.76
Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. J Endocrinol (1996) 0.76
Removal of osteoclast bone resorption products by transcytosis. Science (1997) 2.08
Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J Bone Miner Res (1991) 1.67
Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol (1999) 1.59
Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int (1986) 1.55
Carbonic anhydrase III protects cells from hydrogen peroxide-induced apoptosis. FASEB J (1999) 1.53
Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol (1984) 1.52
Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res (2000) 1.52
Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol (1995) 1.50
Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem (2001) 1.33
Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone (1998) 1.26
Beta 1 integrins and osteoclast function: involvement in collagen recognition and bone resorption. Bone (1996) 1.23
Characterization of circulating human osteoclast progenitors: development of in vitro resorption assay. Calcif Tissue Int (2005) 1.23
The mechanical strength of bone in different rat models of experimental osteoporosis. Bone (1995) 1.20
Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem (1999) 1.19
Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol (1996) 1.19
Pancreatic carcinomas deposit laminin-5, preferably adhere to laminin-5, and migrate on the newly deposited basement membrane. Am J Pathol (1997) 1.16
Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts. J Cell Sci (1997) 1.14
Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst (1993) 1.13
Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet (1982) 1.11
Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res (2000) 1.09
Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem (2000) 1.08
Cytoskeletal changes in osteoclasts during the resorption cycle. Microsc Res Tech (1996) 1.06
Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface. J Cell Biol (1991) 1.02
Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology (2001) 1.02
Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int (2002) 1.01
Spatial organization of microfilaments and vitronectin receptor, alpha v beta 3, in osteoclasts. A study using confocal laser scanning microscopy. J Cell Sci (1993) 1.00
Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res (2001) 1.00
Unchanged protein binding and the increase of serum diazepam levels after food intake. Acta Pharmacol Toxicol (Copenh) (1977) 0.98
Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem (2001) 0.98
Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res (1997) 0.97
The transfer of diazepam across the placenta during labour. Acta Obstet Gynecol Scand (1973) 0.97
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology (2000) 0.96
Hormone regulation of human prostate in organ culture. Cancer Res (1993) 0.96
Human pharmacokinetics of nitrazepam: effect of age and diseases. Eur J Clin Pharmacol (1979) 0.95
Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology (1999) 0.95
Bone-resorbing osteoclasts reveal a dynamic division of basal plasma membrane into two different domains. J Cell Sci (1996) 0.94
Secondary prevention of urinary tract infections. The role of trimethoprim alone. Ann Clin Res (1983) 0.94
Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas (2002) 0.94
Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis (2005) 0.94
Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest (2001) 0.94
Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif Tissue Int (2004) 0.93
Comparison of two gas-liquid chromatographic methods for the determination of nitrazepam in plasma. J Chromatogr (1977) 0.92
The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int (1994) 0.92
Comparison of midazolam and flunitrazepam for night sedation. A randomised double-blind study. Anaesthesia (1982) 0.91
The effect of oral glucose tolerance test on serum osteocalcin and bone turnover markers in young adults. Calcif Tissue Int (2011) 0.91
Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J (1997) 0.91
Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum. Clin Chem (2000) 0.90
Biocompatibility evaluation of dura mater substitutes in an animal model. Neurol Res (2001) 0.90
Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest (1994) 0.90
FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene (2001) 0.90
Expression of E- and N-cadherin in renal cell carcinomas, in renal cell carcinoma cell lines in vitro and in their xenografts. Int J Cancer (1995) 0.90
Calcitonin promotes osteoclast survival in vitro. Mol Cell Endocrinol (1996) 0.89
Ergosterol peroxide, an active compound from Inonotus radiatus. Planta Med (1989) 0.89
Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp Cell Res (1998) 0.89
Effect of impact exercise on bone metabolism. Osteoporos Int (2009) 0.89
High active isoenzyme of carbonic anhydrase in rat calvaria osteoclasts. Immunohistochemical study. Histochemistry (1983) 0.89
Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem (1999) 0.89
Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology (1991) 0.87
Studies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphatase. Arch Biochem Biophys (1998) 0.87
Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats. J Bone Miner Res (1998) 0.87
Tartrate-resistant acid phosphatase facilitates hydroxyl radical formation and colocalizes with phagocytosed Staphylococcus aureus in alveolar macrophages. Biochem Biophys Res Commun (2001) 0.87
HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women. Maturitas (1997) 0.87
Effect of age on the pharmacokinetics and sedative of flunitrazepam. Int J Clin Pharmacol Ther Toxicol (1981) 0.87
Expression of testosterone-dependent enzyme, carbonic anhydrase III, and oxidative stress in experimental alcoholic liver disease. Dig Dis Sci (1999) 0.87
Cell structure and function and response to chemotherapy in tumors heterotransplanted into the subrenal capsule of mice and rats. Eur J Cancer Clin Oncol (1985) 0.87
Calcitonin, prostaglandin E2, and dibutyryl cyclic adenosine 3',5'-monophosphate disperse the specific microfilament structure in resorbing osteoclasts. J Histochem Cytochem (1990) 0.86
Flunitrazepam versus placebo premedication for minor surgery. Acta Anaesthesiol Scand (1979) 0.86
Consecutive expression of carbonic anhydrase isoenzymes during development of rat liver and skeletal muscle differentiation. J Histochem Cytochem (1989) 0.86
A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol (1986) 0.85
Pre-clinical subdural tissue reaction and absorption study of absorbable hemostatic devices. Neurol Res (2001) 0.85
Indirect androgenic control of citrate accumulation in rat ventral prostate. Arch Androl (1982) 0.85
Effect of clodronate treatment on established bone loss in ovariectomized rats. Bone (1998) 0.85
Exercise can provide protection against bone loss and prevent the decrease in mechanical strength of femoral neck in ovariectomized rats. J Bone Miner Res (1994) 0.85
Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer (2000) 0.84
Alteration in the mechanical competence and structural properties in the femoral neck and vertebrae of ovariectomized rats. J Bone Miner Res (1999) 0.84
Plasma nitrazepam concentrations after an acute intake and their correlation to sedation and serum growth hormone levels. Acta Pharmacol Toxicol (Copenh) (1977) 0.84
Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice. Int J Cancer (1991) 0.84
Cerebrospinal-fluid concentration of diazepam and its metabolites in man. Acta Pharmacol Toxicol (Copenh) (1975) 0.84
Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int J Cancer (1995) 0.84
Interaction of male and female sex hormones in cultured rat prostate. Prostate (1987) 0.84
A pharmacokinetic and pharmacodynamic study of flunitrazepam. Int J Clin Pharmacol Ther Toxicol (1982) 0.84
Immunoelectron microscopic localization of carbonic anhydrase III in rat skeletal muscle. Histochemistry (1986) 0.84
Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. Int J Cancer (1996) 0.84
Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology (1996) 0.84
Osteocyte-derived HB-GAM (pleiotrophin) is associated with bone formation and mechanical loading. Bone (2009) 0.84
Osteoclasts and a small population of peripheral blood cells share common surface antigens. Calcif Tissue Int (1990) 0.84
In vitro and in vivo studies of a promising antileukemic thymidine analogue, 5-hydroxymethyl-2' deoxyuridine. Biochem Pharmacol (1986) 0.83
Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone (1997) 0.83
Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic cells. Res Exp Med (Berl) (1991) 0.83
Estrogen and bone metabolism. Maturitas (1996) 0.83